Abstract
Neuroimaging faces a reproducibility crisis, where studies on small, heterogeneous datasets produce unreliable brain-wide associations and AI models that fail to generalize. To address this, we introduce GenBrain, a generative foundation model pretrained on approximately 1.2 million 3D scans from over 44,000 individuals across 34 imaging modalities to learn a population prior of brain structure and function. Crucially, GenBrain enables rapid, data-efficient adaptation, allowing any targeted study to generate biologically valid synthetic cohorts, conditioned on demographics, disease status, or other modalities, to augment statistical power and enhance generalizability. We demonstrate GenBrain’s transformative utility across 81 independent datasets spanning diverse populations, protocols, and clinical conditions. For image-level tasks, it achieves state-of-the-art performance in image enhancement and cross-modality synthesis while preserving subject-specific neurobiology. In population neuroscience, synthetic cohorts from GenBrain stabilize effect-size estimates and significantly improve the reproducibility of brain-wide association studies. For clinical AI, disease-specific fine-tuning of GenBrain substantially boosts the cross-site generalizability of prediction models. Finally, we prove its direct translational value when adapted to unseen modality and scarce clinical stroke data. GenBrain significantly improves predictions of acute stroke severity and chronic aphasia, demonstrating actionable utility under extreme data scarcity. By empowering small-scale studies with large-scale population priors, GenBrain provides a unified framework for more reproducible and clinically generalizable neuroimaging analysis.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of UK Biobank Ethics Advisory Committee gave ethical approval for this work. All analyses were performed on de-identified data obtained under UK Biobank application number 19542.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
The individual-level neuroimaging data used in this study were obtained from UK Biobank (https://www.ukbiobank.ac.uk/), Schizophrenia and ZIC-AD (https://zib.fudan.edu.cn/), MDD (https://rfmri.org/REST-meta-MDD), ADNI(https://adni.loni.usc.edu/), ABIDE (https://fcon_1000.projects.nitrc.org/indi/abide/), SOOP (https://openneuro.org/datasets/ds004889/versions/1.1.2), and ARC (https://openneuro.org/datasets/ds004884/versions/1.0.2).





